X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Dr. Reddy's has received exclusive rights to market and distribute a first-in-class innovative drug Lyfaquin in India. Developed by Pharmazz, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock.
Lead Product(s): Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 22, 2024
Details:
Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: Tycamzzi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: Tyvalzi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2023
Details:
Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the same indication.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: Tycamzzi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ischemic stroke patients.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: Tycamzzi
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: Tycamzzi
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: PMZ-1620
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: Tycamzzi
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
The positive results seen in the Phase III study indicate that Lyfaquin (centhaquine) is a highly safe and efficacious resuscitative agent as an adjuvant to the standard of care and would be a addition to the U.S. Military’s medical resources that can save numerous lives.
Lead Product(s): Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemic stroke.
Lead Product(s): Sovateltide
Therapeutic Area: Neurology Product Name: PMZ-1620
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
